Last reviewed · How we verify

Staphylococcal infection of skin — Treatment Landscape & Competitive Intelligence

Staphylococcal infection of skin (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Staphylococcal infection of skin, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Dalvance DALBAVANCIN AbbVie Lipoglycopeptide Antibacterial 2014-01-01
Orbactiv ORITAVANCIN Melinta Therap Lipoglycopeptide Antibacterial 2014-01-01
Orbactiv Orbactiv Melinta Therapeutics, LLC
Xydalba Xydalba Correvio International Sarl

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. AbbVie · 1 drug in Staphylococcal infection of skin
  2. Correvio International Sarl · 1 drug in Staphylococcal infection of skin
  3. Melinta Therap · 1 drug in Staphylococcal infection of skin
  4. Melinta Therapeutics, LLC · 1 drug in Staphylococcal infection of skin

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Staphylococcal infection of skin:

Cite this brief

Drug Landscape (2026). Staphylococcal infection of skin — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/staphylococcal-infection-of-skin. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing